标题
Synthesis of site-specific antibody-drug conjugates using unnatural amino acids
作者
关键词
-
出版物
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 109, Issue 40, Pages 16101-16106
出版商
Proceedings of the National Academy of Sciences
发表日期
2012-09-18
DOI
10.1073/pnas.1211023109
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
- (2012) Ben-Quan Shen et al. NATURE BIOTECHNOLOGY
- Site-specific DNA-antibody conjugates for specific and sensitive immuno-PCR
- (2012) S. A. Kazane et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody–Drug Conjugates in Rats
- (2011) C. Andrew Boswell et al. BIOCONJUGATE CHEMISTRY
- Selective Formation of Covalent Protein Heterodimers with an Unnatural Amino Acid
- (2011) Benjamin M. Hutchins et al. CHEMISTRY & BIOLOGY
- Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates
- (2011) Robert Y. Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Site-Specific Coupling and Sterically Controlled Formation of Multimeric Antibody Fab Fragments with Unnatural Amino Acids
- (2011) Benjamin M. Hutchins et al. JOURNAL OF MOLECULAR BIOLOGY
- Targeting activated integrin αvβ3 with patient-derived antibodies impacts late-stage multiorgan metastasis
- (2010) Karin Staflin et al. CLINICAL & EXPERIMENTAL METASTASIS
- Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
- (2010) J. R. Junutula et al. CLINICAL CANCER RESEARCH
- Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
- (2010) N. M. Okeley et al. CLINICAL CANCER RESEARCH
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
- (2010) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Comment Re: MDA-MB-435 and M14 Cell Lines: Identical but not M14 Melanoma?
- (2009) A. Hollestelle et al. CANCER RESEARCH
- MDA-MB-435 and M14 Cell Lines: Identical but not M14 Melanoma?
- (2009) Ann F. Chambers CANCER RESEARCH
- An Enhanced System for Unnatural Amino Acid Mutagenesis in E. coli
- (2009) Travis S. Young et al. JOURNAL OF MOLECULAR BIOLOGY
- The Pharmacologic Basis for Antibody-Auristatin Conjugate Activity
- (2009) S. C. Alley et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
- (2009) J. S. Ross et al. ONCOLOGIST
- Novel Peptide Linkers for Highly Potent Antibody−Auristatin Conjugate
- (2008) Svetlana O. Doronina et al. BIOCONJUGATE CHEMISTRY
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Potent Anticarcinoma Activity of the Humanized Anti-CD70 Antibody h1F6 Conjugated to the Tubulin Inhibitor Auristatin via an Uncleavable Linker
- (2008) E. Oflazoglu et al. CLINICAL CANCER RESEARCH
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
- (2008) Jagath R Junutula et al. NATURE BIOTECHNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started